Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conor Corio

This article was originally published in The Gray Sheet

Executive Summary

Firm announces initiation of the 150-patient RAPID trial to evaluate its Corio pimecrolius-eluting stent in Brazil and Europe on May 11. The drug - licensed from Novartis in March - prevents inflammation, which is believed to be a primary cause of restenosis, according to Conor Medsystems. Data from the study will be compared to historical controls from the firm's EuroSTAR study, which evaluated its CoStar paclitaxel-eluting stent. The trial also will evaluate a reduced duration of anti-platelet therapy following stent implantation. Conor expects to complete enrollment for the RAPID study in the second half of this year, with initial results available in 2007. The firm also plans to test a drug-eluting stent that combines pimecrolius and paclitaxel (1"The Gray Sheet" Feb. 20, 2006, p. 7)...
Advertisement

Related Content

Conor CoStar Cleared For European Launch; Firm Modifies U.S. Trial Design
Conor CoStar Cleared For European Launch; Firm Modifies U.S. Trial Design
Advertisement
UsernamePublicRestriction

Register

MT023538

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel